key: cord-0721785-3zhstfss authors: Barchetta, Ilaria; Gisella Cavallo, Maria; Giorgio Baroni, Marco title: COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications date: 2020-04-23 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108165 sha: 3871dbafad73663ab0801123e0626cc328a72cf3 doc_id: 721785 cord_uid: 3zhstfss nan Ilaria Barchetta infection of primary human bronchial epithelial cells. Furthermore, transgenic mice were made susceptible to MERS-CoV by expressing human DPP4 [3] , and these knock-in mice had a lethal form of lung disease, characterized by a strong inflammatory response [3] [4] . Based on these observations, Iacobellis suggest that DPP4 may represent a potential target for DPP4 inhibitors for preventing and/or reducing the risk and progression of the acute respiratory complications that T2DM may add to the COVID-19 infection. However, there are some points to consider carefully before claiming possible novel therapeutic approaches to COVID-19. The potential interaction between SARS-CoV-2 spike glycoproteins and DPP4 has been predicted by structural studies [5] , but needs confirmation in human cells. Moreover, Iacobellis does not take into account that the same authors that demonstrated human DPP4 as a functional receptor for the spike protein of the MERS-Co-V [2] showed that hCoV-EMC infection could not be blocked by the DPP4 inhibitors sitagliptin, vildagliptin and saxagliptin, probably because these inhibitors do not target the binding interface between the S1 domain of hCoV and the receptor. So, the potential role for DPP4 inhibition may not be as important as suggested. There is, however, a point worth taking from Iacobellis' remarks. We have shown that higher plasma DPP4 is evident in obesity, metabolic syndrome and type 2 diabetes [6] and increases with aging [7] , all representing significant risk factors for unfavourable COVID-19 outcomes [8] . Thus, increased DPP4 may represent a driver for clinical severity in SARS-COV2 infection. On one side, the broad DPP4 distribution could contribute to explain the large number of SARS-COV2 target organs, which are more than those expressing ACE2 receptors, identified as the main SARS-COV2 receptor so far [8] . On the other, DPP4 levels may, at least in part, determine COVID-19 severity, reflecting the accessibility of SARS-COV2 to target cells, tissues and organs, and may explain the high incidence of mortality in severe COVID-19. Therefore, it may be warranted to further investigating the utility of DDP4 measurement. Plasma DPP4 measurement could represent an easy tool for risk stratification in SARS-COV2 infected patients, particularly in highly susceptible populations as those with Diabetes or other metabolic conditions, and a marker of disease progression and response to treatment in COVID-19. COVID-19 and diabetes: Can DPP4 inhibition play a role? Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus Increased Plasma DPP4 Activity Is Predictive of Prediabetes and Type 2 Diabetes Onset in Chinese Over a Four-Year Period: Result From the China National Diabetes and Metabolic Disorders Study Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Funding None